Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib
Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib
复制标题
DOI：
10.4251/wjgo.v8.i7.555
复制
发表时间：
2016-07-15
影响因子：
3
通讯作者：
Kim, Chang Duck
中科院分区：
文献类型：
--
作者：
Lee, Jae Min;Lee, Hong Sik;Kim, Chang Duck
目的：评价全身性炎症标志物作为晚期胰腺癌（PC）预后因素的价值。方法：回顾性收集2011 - 2014年接受吉西他滨和厄洛替尼联合化疗治疗PC的82例患者的资料。分析数据包括中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值、c反应蛋白（CRP）与白蛋白（CRP/Alb）比值。Kaplan-Meier曲线、单因素和多因素Cox比例风险回归分析用于确定与无进展生存期（PFS）和总生存期（OS）相关的预后因素。结果：单因素分析显示NLR （P = 0.049）和CRP/Alb比值（P = 0.047）与PFS相关的预后价值，炎症标志物的增加与OS相关的不良预后呈正相关。多因素分析确定NLR增加（风险比= 2.76,95% CI: 1.33-5.75, P = 0.007）是不良OS的独立预后因素。在接受吉西他滨和厄洛替尼联合化疗的患者中，PLR与患者预后之间没有关联。Kaplan-Meier方法和log-rank检验确定NLR为> 5或CRP/Alb比值为> 5的患者与PFS和OS相关的预后明显较差。结论：基于全身性炎症的标志物，包括NLR和CRP/Alb比值的增加，可能有助于预测PC预后。
AIM: To evaluate the value of systemic inflammation-based markers as prognostic factors for advanced pancreatic cancer (PC).METHODS: Data from 82 patients who underwent combination chemotherapy with gemcitabine and erlotinib for PC from 2011 to 2014 were collected retrospectively. Data that included the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio, and the C-reactive protein (CRP)-to-albumin (CRP/Alb) ratio were analyzed. Kaplan-Meier curves, and univariate and multivariate Cox proportional hazards regression analyses were used to identify the prognostic factors associated with progression-free survival (PFS) and overall survival (OS).RESULTS: The univariate analysis demonstrated the prognostic value of the NLR (P = 0.049) and the CRP/Alb ratio (P = 0.047) in relation to PFS, and a positive relationship between an increase in inflammation-based markers and a poor prognosis in relation to OS. The multivariate analysis determined that an increased NLR (hazard ratio = 2.76, 95% CI: 1.33-5.75, P = 0.007) is an independent prognostic factor for poor OS. There was no association between the PLR and the patients' prognoses in those who had received chemotherapy that comprised gemcitabine and erlotinib in combination. The Kaplan-Meier method and the log-rank test determined significantly worse outcomes in relation to PFS and OS in patients with an NLR > 5 or a CRP/Alb ratio > 5.CONCLUSION: Systemic inflammation-based markers, including increases in the NLR and the CRP/Alb ratio, may be useful for predicting PC prognoses.